New vaccine aims to snuff out the common cold
NCT ID NCT07399132
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new vaccine called APL-10456 that targets rhinovirus, the main cause of the common cold. About 144 healthy adults, both younger (18-54) and older (55+), will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APL-10456-Vaccine
What this could lead to
If successful, this could lead to a vaccine that prevents common colds caused by rhinovirus.
What could go wrong
This is a very early Phase 1 trial with only 144 healthy volunteers. The vaccine may not produce a strong immune response or could have unexpected side effects. Success in early phases does not guarantee a usable vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHINOVIRUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emeritus Research
Melbourne, Victoria, 3124, Australia
-
Veritus Research
Melbourne, Victoria, 3153, Australia